Rethinking Checkpoint Blockade for Cancer Treatment
Vycellix Sweden is a contributing member of the REPRESSIT Consortium with the grant-funded mission to generate a technology platform for off-the-shelf RIPR molecules (Receptor Inhibition by Phosphatase Recruitment) targeting any tyrosine phosphatase carrying inhibitory immune receptor.
Link to Nature Publication: https://www.nature.com/articles/s41586-020-2851-2
Our REPRESSIT Consortium aims to generate Proof-of-Concept for full in vivo functionality of RIPR molecules against diverse T and NK cell receptors in preclinical tumor models.
Our goal is to pioneer the development of next-generation checkpoint therapeutics with unprecedented efficacy for as broad a population of cancer patients in need as possible.
For more details on the REPRESSIT program, please visit: https://www.repressit.eu/
